Lumen Technologies Inc vs Nuwellis Inc — how do they compare? Lumen Technologies Inc trades at $5.29 (market cap $5.73B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: Lumen Technologies Inc is far larger — about 2604.5× Nuwellis Inc's market cap, and Nuwellis Inc is more actively traded (121,544 versus 17,079,799). Which is the better fit depends on your goals — on Pluang, investors hold Lumen Technologies Inc for 40 Days and Nuwellis Inc for 26 Days on average.
| LUMN | NUWE | |
|---|---|---|
Market Cap | $5.73B | $2.20M |
Volume | 17,079,799 | 121,544 |
Sector | Media | Health |
52-Week High | $11.83 | $146.65 |
52-Week Low | $5.53 | $0.68 |
Typical Hold Time | 40 Days | 26 Days |
Enterprise Value | $17.35B | -$1.52M |
Signals from Pluang's Aura AI — not financial advice
Lumen Technologies (LUMN) trades at $5.28, down 10.66% in the last session, reflecting ongoing investor concerns. The stock shows bearish technical signals with mixed earnings performance - beating estimates in Q4 2025 and Q2 2026 but missing in Q1 2026. Despite revenue declining from $17.5B in 2022 to $12.4B in 2025, the company maintains strong operating cash flow of $4.7B and is strategically pivoting toward AI networking services.
LUMN presents a high-risk turnaround opportunity with significant debt burden ($17.5B long-term) and negative profitability metrics. The AI-focused strategy shows promise but faces execution risk against steep legacy revenue declines. Analyst consensus remains cautious with 61% hold ratings, suggesting investors await concrete evidence of sustainable growth before committing.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →